missing translation for 'onlineSavingsMsg'
Learn More
Learn More
MET Monoclonal Antibody (OTI3G5), TrueMAB™, OriGene
Mouse Monoclonal Antibody
Brand: Origene Technologies TA805796
This item is not returnable.
View return policy
Description
MET is a tyrosine kinase receptor for the hepatocyte growth factor. It is linked to functions such as cell proliferation, scattering, morphogenesis, and survival. Ligand binding at the cell surface induces autophosphorylation of MET that provides docking sites for downstream signaling molecules. After activation of the ligand, MET interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, and STAT3. There interactions lead to the activation of signaling cascades including RAS-ERK, PI3, kinase-AKT, and PLCgamma-PKC. MET plays a role in embryonic development including gastrulation, development of muscles and neurons, angiogenesis, and kidney formation. It also plays a role in adults including wound healing, organ regeneration, and tissue remodeling. MET has been linked to cancers including gastric, renal, and breast; therefore, making it a target for cancer therapeutics and diagnostic testing.Specifications
| MET | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
| P08581 | |
| MET | |
| Human recombit protein fragment corresponding to amino acids 570-885 of human MET produced in E.coli. | |
| 100 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG1 |
| Western Blot | |
| OTI3G5 | |
| Unconjugated | |
| MET | |
| AUTS9, DFNB97, HGFR, RCCP2, c-Met | |
| Mouse | |
| Affinity Chromatography | |
| RUO | |
| 4233 | |
| -20° C, Avoid Freeze/Thaw Cycles | |
| Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction